Summary of the Keystone Symposium “Origins of allergic disease: Microbial, epithelial and immune interactions,” March 24-27, Tahoe City, California - 06/04/20
Abstract |
The aims of the Keystone Symposium conference, “Origins of allergic disease: Microbial, epithelial and immune interactions” were to present and discuss potential microbial-epithelial-immune interactions underlying the early-life origins of allergic disorders, as well as immune mechanisms that might suggest novel disease prevention or intervention strategies. Cross-talk and sharing of ideas among participating experts in basic science and clinical aspects of allergic diseases provided substantial insight into the concept of allergic disorders as a systems disease. The overriding message distilled from the discussions was that damage to epithelial surfaces lies at the origin of the various manifestations of allergic disease. The epithelium of the lungs, gut, and skin, which operates as a critical sensor of environmental stimuli, is besieged by an onslaught of contemporary environmental forces including an altered microbiome, air pollution, food allergens in a changed diet, and chemicals in modern detergents. Collectively, this onslaught leads to alterations of lung, skin, or gut epithelial surfaces, driving a type 2 immune response that underlies most, if not all, of the atopic diseases. Possible remedies for treatment and prevention of allergic diseases were discussed, including a precision medicine approach using biologics, oral desensitization, targeted gut microbiome alterations, and behavior alteration.
El texto completo de este artículo está disponible en PDF.Key words : Atopic dermatitis, food allergy, asthma, microbiome, epithelial barrier
Abbreviations used : AD, CC16, CMA, DC, EoE, FA, FLG, LoF, NPM, RV, TSLP
Esquema
This work was supported by the Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California (R.H.D., W.Z., and K.C.N.). D.Y.M.L. is supported by National Institutes of Health grants 1U19AI117673, 5R01AR41256, UL1TR002535, 1UM2AI130836, and UM1AI130780. |
|
Disclosure of potential conflict of interest: K. C. Nadeau reports grants from the National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research & Education (FARE), End Allergies Together, Allergenis, and Ukko Pharma; is grant awardee at NIAID, National Institute of Environmental Health Sciences, National Heart, Lung, and Blood Institute (NHLBI), and the Environmental Protection Agency; is involved in clinical trials with Regeneron, Genentech, AImmune Therapeutics, DBV Technologies, AnaptysBio, Adare Pharmaceuticals, and Stallergenes Greer; received research sponsorship by Novartis, Sanofi, Astellas, and Nestle; is Data and Safety Monitoring Board member at Novartis and NHLBI; cofounded BeforeBrands, Alladapt, ForTra, and Iggenix; is Director of FARE and World Allergy Organization (WAO) Center of Excellence; and received personal fees from Regeneron, Astrazeneca, ImmuneWorks, and Cour Pharmaceuticals. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 145 - N° 4
P. 1072 - avril 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?